The European Hematology Association 2022 Hybrid Congress (EHA2022)

Pegcetacoplan bests SoC for PNH in PRINCE update

Elvira Manzano, 20220719000000

Treatment with pegcetacoplan improves the quality of life (QoL) of patients with paroxysmal nocturnal haemoglobinuria (PNH) who were naïve to complement inhibitor therapy, according to the PRINCE study update presented at EHA 2022. This comes with the added benefit of disease control.

Second-line axi-cel improves EFS in elderly patients with R/R LBCL

Elaine Soliven, 20220716000000

Second-line treatment with the CAR* T-cell therapy axicabtagene ciloleucel (axi-cel) led to significantly longer event-free survival (EFS) in patients aged ≥65 years with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) compared with standard of care (SoC), according to a preplanned subgroup analysis of the ZUMA-7** trial presented at EHA 2022.

Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL

Roshini Claire Anthony, 20220713180001

A time-limited regimen of venetoclax plus obinutuzumab with or without ibrutinib improved progression-free survival (PFS) in fit, treatment-naïve patients with chronic lymphocytic leukaemia (CLL), according to results of the phase III GAIA/CLL13 trial presented at EHA 2022.

Quizartinib bounces back, doubles OS in FLT3-ITD-positive AML

Elvira Manzano, 20220709000000

The oral FLT3 inhibitor quizartinib more than doubled overall survival (OS) when added to first-line chemotherapy in patients with newly diagnosed FLT3-ITD*-positive acute myeloid leukaemia (AML) in the phase III QuANTUM-First** trial

Age the biggest risk factor for COVID-19 mortality in haematological cancer patients

Roshini Claire Anthony, 20220707180001

A study conducted in England has shown that in patients with haematological malignancy, the risk of COVID-19–related mortality is greatly influenced by age.

Post-transplant KRd a new SoC for MM?

Audrey Abella, 20220707100000

In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).

Longer luspatercept treatment continues to benefit TDT patients

Audrey Abella, 20220706100000

Patients with transfusion-dependent β-thalassemia (TDT) continued to benefit from over 3 years of treatment with luspatercept, a first-in-class erythroid maturation agent that enhances late-stage erythropoiesis, according to the longer-term efficacy analysis of the phase III BELIEVE study.

Long-term data show sustained benefit of sutimlimab for CAD

Audrey Abella, 20220705100000

The final 2-year (part B) results of the phase III CARDINAL study continued to demonstrate the favourable risk-benefit profile of sutimlimab, a first-in-class selective anti-C1s classical complement pathway (CP) inhibitor, for the management of cold agglutinin disease (CAD), a rare chronic, autoimmune haemolytic anaemia characterized by classical CP-mediated haemolysis.

Decitabine as good as, but safer than, chemo in AML

Elvira Manzano, 20220701000000

Extended treatment with decitabine is as good as, but safer than, standard induction chemotherapy (IC) in older patients with acute myeloid leukaemia (AML), according to a phase III study presented at EHA 2022.

Updated ASCEMBL results boost asciminib potential for CML

Audrey Abella, 20220628100000

In the week-96 analysis of the phase III ASCEMBL trial, the first BCR::ABL1 STAMP* inhibitor asciminib sustained superiority over bosutinib for individuals with CML-CP** who have failed ≥2 lines of prior tyrosine kinase inhibitors (TKIs).